Identifying microbiome biomarkers in cancer patients
Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic
Gustave Roussy, Cancer Campus, Grand Paris · NCT04567446
This study is trying to find helpful markers in the gut bacteria of cancer patients starting treatment to see if they can improve care and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1100 (estimated) |
| Sex | All |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris (other) |
| Locations | 9 sites (Villejuif, Val De Marne and 8 other locations) |
| Trial ID | NCT04567446 on ClinicalTrials.gov |
What this trial studies
This observational study aims to discover microbiome-based biomarkers in patients diagnosed with cancer who are about to begin treatment. It involves the collection of biological samples, including stool and blood, from multiple centers to analyze the microbiome's role in cancer. The study seeks to understand how these biomarkers can be utilized to improve patient outcomes and tailor treatments. Participants will provide informed consent and must be affiliated with a social security scheme.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with cancer who are starting anticancer treatment and can provide informed consent.
Not a fit: Patients who are pregnant, lactating, or unable to give consent due to legal or administrative reasons will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of new diagnostic tools and personalized treatment strategies for cancer patients.
How similar studies have performed: While the approach of using microbiome analysis in cancer research is gaining traction, this specific study's methodology is relatively novel and untested in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with cancer who will start treatment anticancer (see cohorts). * Patient information and signature of the consent form before any specific procedure for the study. The patient must be able and must be inclined to cooperate in the study procedures. * Patient affiliated to a social security scheme or beneficiary of a similar scheme. Exclusion Criteria: * Pregnant or lactating woman * Patient under guardianship or curatorship or deprived of liberty by a decision judicial or administrative or patient unable to give his consent.
Where this trial is running
Villejuif, Val De Marne and 8 other locations
- Gustave Roussy — Villejuif, Val De Marne, France (RECRUITING)
- Centre hospitalier du Pays d'Aix — Aix-en-Provence, France (RECRUITING)
- Centre Pierre Curie — Beuvry, France (RECRUITING)
- Clinique du Flandre — Coudekerque-Branche, France (RECRUITING)
- CHRU Lille - Hôpital Calmette — Lille, France (RECRUITING)
- Centre Léon Bérard — Lyon, France (RECRUITING)
- Hôpital St Louis — Paris, France (RECRUITING)
- Hôpital Foch — Suresnes, France (RECRUITING)
- Centre hospitalier TOULON - Sainte-Musse — Toulon, France (RECRUITING)
Study contacts
- Study coordinator: Laurence Zitvogel, MD, PhD
- Email: laurence.zitvogel@gustaveroussy.fr
- Phone: +33 (0)1 42 11 42 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer